Efficacy and safety of ombitasvir/paritaprevir/ritonavir-based therapy in HCV patients with chronic kidney disease

Mohammad El-Sayed,Magdy Elserafy,Maissa El Raziky,Wafaa Elakel,Yasmin Saad,Tarek Fayad,Mohamed Korany,Mai Mehrez,Rabab Salama,Maged Mahrous, Ayman Zaki,Mohamed Hassany,Islam Ammar,Kadry Elsaeed,Yehia Elshazly,Wahid Doss

Arab Journal of Gastroenterology（2023）

引用 1|浏览8

暂无评分

摘要

Ombitasvir/paritaprevir/ritonavir-based therapy in chronic HCV patients with CKD is highly effective, with minimal side effects despite ribavirin-induced anemia.

查看译文

关键词

Ombitasvir/paritaprevir/ritonavir,HCV,Chronic kidney disease

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要